LIVE

LKFT

Lakefront Biotherapeutics N.V.

LKFT

NASDAQ·Healthcare·Biotechnology·Mkt cap $2.0B

$30.34

+2.48%

View full research view

Our plain-language verdict, the thesis, risk factors, and what is changing about the business.

View research view

52-Week Range

$26.42 - $37.78

P/E

118.93

Fwd P/E

-10.67

Beta

0.13

Div Yield

0.00%

Avg Vol

163.4K

Shares Out

Mkt Cap

$2.0B

Price action

Price chart

Up 3.7% over the trailing year

1W
1M
3M
6M
YTD
1Y
5Y
MAX

Total returns

Price performance

Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.

Why we rate it this way

The thesis at a glance

Bull and bear case · plain-English context across the five lenses we evaluate.

Bull Case

No bull reasons captured for this rating yet.

Bear Case

1 risk

  • Low volatility (beta 0.1).

Growth

Profitability at risk

Value

Deep value opportunity - significant discount to sector peers

Momentum

Stable

+0.6% over 3m

Quality

Excellent

Mixed fundamentals

Dividend

None

No dividend

Earnings track record

Recent earnings results

AI-summarized recap of last quarter, plus the surprise on every print.

Next: Aug 10, 2026

LATEST RECAP

Earnings recap unavailable for this period.

EPS surprise · last 4Q

Q1 26

$0.26

Next: Aug 10, 2026

Revenue trend · last 1Q

Q1 26

$7.5M

Margins · last 1Q

Profit

223.6%

Wall Street consensus

1 analyst · 0% Buy

Live ratings and price targets aggregated across covering analysts.

Buy

0%

Hold

1

100%

Sell

0%

Median Price Target

Latest: RBC Capital · Feb 25, 2026

vs Industry

How LKFT stacks vs Biotechnology

Stock metrics vs industry averages. Green = better than industry.

Industry comparison data unavailable for this stock.

Related

Peers & themes

Peers

No peer data available.

Themes

No themes assigned.